Stock Ratings / Health Care / LMRI / forecast

CSTL (60) TRUP (64) FRNM (31) ALHC (67) ⌘ Pro Terminal →

Lumexa Imaging Holdings Inc. (LMRI) 12-Month Stock Forecast & Price Target Cone

$11.73 +0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lumexa Imaging Holdings Inc. (LMRI) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LMRI)Realized 20D OHLCV Swing Band: ±9.1%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LMRI Position Size: $10,000

Shares at $11.73: 852.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $9.15

$7,801

$-2,199 (-22.0%)

12M Consensus BaseTarget $11.73

$10,000

+$0 (+0.0%)

12M Bull Case BreakoutTarget $20.42

$17,408

+$7,408 (+74.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$12	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$19	69%	B
JP MorganUS Large-Cap Research	HOLD	$10	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LMRI)

✓Walkthrough of LMRI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LMRI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.57%⚡ TESTING RESISTANCE

2026-10-30O $11.80H $11.88L $11.26C $11.73VOL 244.5K

RES: $11.96SUP: $9.82SMA50: $11.11SMA200: $11.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LMRI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LMRI Butterfly Map → + Track LMRI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LMRI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LMRI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LMRI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LMRI)

Health Care Rank #228 of 1016 ⚔️ CSTL vs LMRI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LMRI vs. CSTL, TRUP, FRNM, ALHC)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lumexa Imaging Holdings Inc. (LMRI) ranks #228 by composite RQD confidence (58/100, grade D+) and #347 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. ALHC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with LMRI at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LMRI ACTIVE Lumexa Imaging Holdings Inc.	D+	58/100	—	—	—	+0.95%	$1.13B	Benchmark Subject
CSTL Castle Biosciences Inc.	C-	60/100	—	79.4%	-9.3%	+4.99%	$1.18B	/cstl-vs-lmri →
TRUP Trupanion Inc.	C	64/100	68.2x	16.1%	3.1%	+2.27%	$1.32B	/trup-vs-lmri →
FRNM Freenome Inc.	E	31/100	—	—	-3.4%	-4.32%	$1.38B	/frnm-vs-lmri →
ALHC Alignment Healthcare Inc.	C+	67/100	—	—	13.9%	-1.47%	$1.67B	/alhc-vs-lmri →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002071288

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lumexa Imaging Holdings Inc. (LMRI) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LMRI closed FY2025 with $1.76B in total assets against $819.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$1.76B	$819.0M

3. LMRI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LMRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lumexa Imaging Holdings Inc. (NASDAQ: LMRI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $11.73 (+0.95% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LMRI ranks #228 in composite RQD confidence.

How does LMRI compare to CSTL and TRUP in the Health Care sector?

Within the Health Care sector (Medical Specialities), LMRI carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CSTL (Castle Biosciences Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC -9.3%, cap $1.18B) and TRUP (Trupanion Inc.) posts a C grade (64/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LMRI?

Per LMRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002071288), Lumexa Imaging Holdings Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $1.76B in total assets and $819.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LMRI trading relative to its 50-day, 200-day, and 52-week technical levels?

LMRI last traded at $11.73 (+0.95% on volume of 200,191 shares), positioning the stock +5.58% above its 50-day simple moving average ($11.11) and +5.68% above its 200-day simple moving average ($11.10). Across its 52-week range of $6.45 to $19.45, LMRI sits at the 40.6% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.1% ($10.66 to $12.80).

LMRI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LMRI's 12-month stock price target?

Lumexa Imaging Holdings Inc. (LMRI) carries a 12-month consensus base price target of $11.73 (+0% from $11.73), with a bull-case target of $20.42 and a bear-case floor of $9.15.